Vion (formerly Oncorx) interesting play on Gene Therapy Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (263)	3/13/2002 1:05:57 PM
From: Jim Oravetz	Read Replies (1) of 370

Vion Pharma Will Formally Introduce New CFO Next Week DOW JONES NEWSWIRES NEW HAVEN, Conn. -- Vion Pharmaceuticals Inc. (VION) Chief Financial Officer Steve Koehler will leave the company for personal reasons. In a press release Wednesday, Vion said a replacement has been appointed, but a formal announcement will be made next week, at the request of the new chief financial officer's present company. Separately, Vion said it will present an update on the status of its clinical trial programs in a conference call scheduled for 11:00 a.m EST Wednesday. Vion said it's "pleased with the trends we are seeing in the clinical trials. We believe that for a company of our size to have four products (Triapine, SHP Prodrugs, TAPET and TAPET CD) in clinical trials, all with good revenue potential, is a major accomplishment." With a cash balance of almost $23 million at the end of 2001, Vion said it continues to manage cash "efficiently and effectively."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next